Impact of ghrelin on vitreous cytokine levels in an experimental uveitis model

Drug Design, Development and Therapy

Volumn 7, Issue , 2013, Pages 19-24

  Turgut, Burak ^a   Gül, Fatih Cem ^a   Daǧli, Ferda ^b   Ilhan, Nevin ^a   Özgen, Metin ^b  

^a FIRAT UNIVERSITY   (Turkey)

^b INONU UNIVERSITY   (Turkey)

Author keywords

Ghrelin; Infliximab; Interleukin 1; Interleukin 6; Tumor necrosis factor alpha; Uveitis

Indexed keywords

CONCANAVALIN A; GHRELIN; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CILIARY BODY; CONTROLLED STUDY; DRUG EFFECT; EDEMA; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROSIS; HISTOPATHOLOGY; INFLAMMATORY CELL; MALE; NONHUMAN; RAT; RETINA; UVEITIS;

GHRELIN; INFLIXIMAB; INTERLEUKIN-1; INTERLEUKIN-6; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS;

ANIMALS; CONCANAVALIN A; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GHRELIN; INJECTIONS, INTRAPERITONEAL; INTERLEUKIN-1; INTERLEUKIN-6; MALE; RATS; RATS, INBRED LEW; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS; VITREOUS BODY;

EID: 84872335398     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S39453     Document Type: Article

References (46)

1. Franks WA, Limb GA, Stanford MR, et al. Cytokines in human intraocular infammation. Curr Eye Res. 1992;11:187-191.
2. de Vos AF, Hoekzema R, Kijlstra A. Cytokines and uveitis: a review. Curr Eye Res. 1992;11:581-597.
3. de Vos AF, van Haren MA, Verhagen C, et al. Kinetics of intraocular tumor necrosis factor and interleukin-6 in endotoxin-induced uveitis in the rat. Invest Ophthalmol Vis Sci. 1994;35:1100-1106.
4. Ebert EC. Infiximab and the TNF-α system. Am J Physiol Gastrointest Liver Physiol. 2009;296:612-620.
5. Hosseini H, Safaei A, Khalili MR, et al. Intravitreal infiximab in experimental endotoxin-induced uveitis. Eur J Ophthalmol. 2009;19: 818-823.
6. Demir T, Gödekmerdan A, Balbaba M, et al. The effect of infiximab, cyclosporine A and recombinant IL-10 on vitreous cytokine levels in experimental autoimmune uveitis. Indian J Ophthalmol. 2006;54: 241-245.
7. Kojima M, Hosoda H, Date Y. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402:656-660.
8. Kojima M, Kangawa K. Ghrelin: structure and function. Physiol Rev. 2005;85:495-522.
9. Aydin S, Ozkan Y, Caylak E, et al. Ghrelin and its biochemical functions. Turkiye Klinikleri J Med Sci. 2006;26:272-283.
10. Wren AM, Seal LJ, Cohen MA, et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab. 2001;86: 5992-5994.
11. Tschop M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature. 2000;407:908-913.
12. Dixit VD, Pyle RS, Schaffer EM, et al. Ghrelin inhibits leptin-and activation induced proinfammatory cytokine expression by human monocytes and T cells. J Clin Invest. 2004;114:57-66.
13. Dembinski A, Konturek SJ, Ceranowicz P. Ghrelin attenuates the development of acute pancreatitis in rat. J Physiol Pharmacol. 2003;54: 561-573.
14. Mathurin P, Gonzalez F, Kerdraon O, et al. The evolution of severe steatosis after bariatric surgery is related to insulin resistance. Gastroenterolog y. 2006;130:1617-1624.
15. Chen J, Liu X, Shu Q, et al. Ghrelin attenuates lipopolysaccharide- induced acute lung injury through NO pathway. Med Sci Monit. 2008; 14:141-146.
16. Granado M, Priego T, Martin AI. Anti-infammatory effect of the ghrelin agonist growth hormone-releasing peptide-2 (GHRP-2) in arthritic rats. Am J Physiol Endocrinol Metab. 2005;288:486-492.
17. Gordon DM. Prednisone and prednisolone in ocular disease. Am J Ophthalmol. 1956;41:593-600.
18. Lightman S. Uveitis: what do we know and how does it help? Clin Experiment Ophthalmol. 2001;29:48-51.
19. Er H, Uzmez E, Doǧan N, et al. The anti-infammatory effects of nitro L arginine (L-NAME) and steroid in concanavalin A induced uveitis. J Med Sci. 1999;29:233-239.
20. Gwon A, Mantras C, Gruber L, et al. Concanavalin A-induced posterior subcapsular cataract: a new model of cataractogenesis. Invest Ophthalmol Vis Sci. 1993;34:3483-3488.
21. Roitt I, Male D. Immunology. International Edition, 6th ed. 1998: 234-240.
22. Kijlstra A. The role of cytokines in ocular inflammation. Br J Ophthalmol. 1994;78:885-886.
23. Abbas AK, Pober JS. Cytokines. Cellular and Molecular Immunology, 3rd ed. Pennsylvania, PA: WB Saunders Company; 1997.
24. Murray PI, Van Haren HR. MAC: aqueous humor interleukin-6 levels in uveitis. Invest Ophthalmol Vis Sci. 1990;31:917-920.
25. Rutanen EM. Cytokines in reproduction. Ann Med. 1993;25: 343-347.
26. Galley HF, Webster NR. The immuno-infammatory cascade. Br J Anaesth. 1996;77:11-16.
27. Hoekzema R, Murray PI, Kijlstra A. Cytokines and intraocular infammation. Curr Eye Res. 1990;9:207-211.
28. de Boer JH, Van Haren MA, Baarsma GS, et al. Analysis of IL-6 levels in human vitreous fuid obtained from uveitis patients, patients with proliferative intraocular disorders and eye bank eyes. Curr Eye Res. 1992;11 Suppl:181-186.
29. Murphy CC, Ayliffe WH, Booth A, et al. Tumor necrosis factor alpha blockade with infiximab for refractory uveitis and scleritis. Ophthalmolog y. 2004;111:352-356.
30. Sfkakis P P, Theodossiadis PG, Katsiari CG, et al. Effect of infiximab on sight-threatening panuveitis in Behcet's disease. Lancet. 2001;35: 295-296.
31. Remicade IV injection [Prescribing information]. Malvern, PA: Centocor; 1999.
32. El-Shabrawi Y, Mangge H, Hermann J. Anti-tumour necrosis factor alpha treatment in chronic recurrent infammation of the anterior seg- ment of the eye in patients resistant to standard immunomodulatory treatment. Ann Rheum Dis. 2003;62:1243-1244.
33. Joseph A, Raj D, Dua HS, et al. Infiximab in the treatment of refractory posterior uveitis. Ophthalmology. 2003;110:1449-1453.
34. Muñoz-Fernández S, Hidalgo V, Fernández-Melón J, et al. Effect of infiximab on threatening panuveitis in Behcet's disease. Lancet. 2001;358:1644-1646.
35. Smith JR, Levinson RD, Holland GN, et al. Differential effcacy of tumor necrosis factor inhibition in the management of infammatory eye disease and associated rheumatic disease. Arthritis Rheum. 2001;45: 252-257.
36. Sartani G, Silver PB, Rizzo LV, et al. Anti tumor necrosis factor alpha therapy suppresses the induction of experimental autoimmune uveo- retinitis in mice by inhibiting antigen priming. Invest Ophthalmol Vis Sci. 1996;37:2211-2218.
37. Xia Q, Pang W, Pan H, et al. Effects of ghrelin on the proliferation and secretion of splenic T lymphocytes in mice. Regul Pept. 2004;122: 173-178.
38. Dixit VD, Taub DD. Ghrelin and immunity: a young player in an old feld. Exp Gerontol. 2005;40:900-910.
39. Chang L, Zhao J, Yang J, et al. Therapeutic effects of ghrelin on endotoxic shock in rats. Eur J Pharmacol. 2003;473:171-176.
40. Korbonits M, Ciccarelli E, Ghigo E, et al. The growth hormone secretagogue receptor. Growth Horm IGF Res. 1999;9:93-99.
41. Pong SS, Chaung LY, Dean DC, et al. Identifcation of a new G-protein- linked receptor for growth hormone secretagogues. Mol Endocrinol. 1996;10:57-61.
42. Rocha-Sousa A, Saraiva J, Henriques-Coelho T, et al. Ghrelin as a novel locally produced relaxing peptide of the iris sphincter and dilator muscles. Exp Eye Res. 2006;83:1179-1187.
43. Katsanos A, Dastiridou A, Georgoulias P, et al. Plasma and aqueous humour levels of ghrelin in open-angle glaucoma patients. Clin Experiment Ophthalmol. 2011;39:324-329.
44. Sehirli O, Sener E, Sener G, et al. Ghrelin improves burn induced multiple organ injury by depressing neutrophil infltration and the release of pro infammatory cytokines. Peptides. 2008;29:1231-1240.
45. Kasimay O, Işeri SO, Barlas A, et al. Ghrelin ameliorates pancreatico- biliary infammation and associated remote organ injury in rats. Hepatol Res. 2006;36:11-19.
46. Erşahin M, Toklu HZ, Erzik C, et al. The antiinfammatory and neu- roprotective effects of ghrelin in subarachnoid hemorrhage-induced oxidative brain damage in rats. J Neurotrauma. 2010;27:1143-1155.